Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Active, not recruiting · NCT02079740 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT02079740 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |